AVXLライブシグナル | Getagraph.comで利益を最大化

売る 109208 min ago

@ $5.61

発行日: 14 2月 2024 @ 05:41

リターン: -34.49%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: -3.28 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:48):

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases...

Stats
本日の出来高	477 266
平均出来高	1.32M
時価総額	297.08M
EPS	$0 ( 2024-02-05 )
次の収益日	( $-0.110 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.74
ATR14	$0.00800 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Missling Christopher U	Buy	73 380	Common Stock
2024-03-28	Missling Christopher U	Sell	73 380	Common Stock
2024-03-28	Missling Christopher U	Sell	73 380	Stock Option (Right to Buy)
2024-02-20	Donhauser Peter D.o.	Buy	50 000	Stock Option (Right to Buy)
2024-02-20	Thomas Steffen	Buy	50 000	Stock Option (Right to Buy)

INSIDER POWER
3.48
Last 100 transactions
Buy: 6 187 971 \| Sell: 2 192 392

ボリューム相関

長: 0.18 (neutral)

短: -0.64 (weak negative)

Signal:(75.514) Neutral

Anavex Life Sciences Corp 相関

10 最も正の相関
BLCM	0.903
VISL	0.903
ALLO	0.899
GURE	0.891
CPIX	0.89
RLMD	0.883
CADL	0.877
CMLF	0.875
ALGS	0.874
ENTA	0.874

10 最も負の相関
XOG	-0.919
BNIXU	-0.893
FIZZ	-0.892
IMRX	-0.872
PT	-0.86
EPZM	-0.857
ANSS	-0.846
WLTW	-0.839
SGEN	-0.838
AMRB	-0.831

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Anavex Life Sciences Corp 相関 - 通貨/商品

-0.08
( neutral )

-0.32
( neutral )

0.00
( neutral )

0.51
( weak )

0.62
( weak )

0.82
( strong )

Anavex Life Sciences Corp 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.600

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.600

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.620

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.540

Financial Reports:

No articles found.

Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.